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Abstract
The low-grade, chronic, systemic inflammatory state that characterizes the aging process
(inflammaging) results from late evolutive-based expression of the innate immune system.
Inflammaging is characterized by the complex set of five conditions which can be described as 1.
low-grade, 2. controlled, 3. asymptomatic, 4. chronic, 5. systemic, inflammatory state, and fits with
the antagonistic pleiotropy theory on the evolution of aging postulating that senescence is the late
deleterious effect of genes (pro-inflammatory versus anti-inflammatory)that are beneficial in early
life. Evolutionary programming of the innate immune system may act via selection on these genetic
traits. Here I propose that the already acquired knowledge in this field may pave the way to a new
chapter in the pathophysiology of autoimmunity: the auto-innate-immunity syndromes. Indeed,
differently from the well known chapter of conventional autoimmune diseases and syndromes
where the main actor is the adaptive immunity, inflammaging may constitute the subclinical
paradigm of a new chapter of autoimmunity, namely that arising from an autoimmune inflammatory
response of the innate-immune-system, an old actor of immunity and yet a new actor of
autoimmunity, also acting as a major determinant of elderly frailty and age-associated diseases.
Auto [innate]immunity: a new chapter of 
autoimmunity
The term "Inflammaging" has been coined by Claudio
Franceschi to explain the now widely accepted phenome-
non that ageing is accompanied by a low-grade chronic,
systemic up-regulation of the inflammatory response and
that the underlining inflammatory changes are also com-
mon to most age-associated diseases [1-8].
From a review of the literature on Inflammaging [1-8] I
suggest that, like acute inflammation is well known to be
associated with the five cardinal features 1. rubor (red-
ness), 2. tumor (swelling), 3. dolor (pain), 4. calor
(warm), 5. functio lesa (loss of function), on the contrary,
inflammaging is characterized by the complex set of five
conditions which can be described as 1. low-grade, 2. con-
trolled, 3. asymptomatic, 4. chronic, 5. systemic, inflam-
matory state.
The inflammatory scenario that characterizes inflammag-
ing constitutes a highly complex response to various sub-
tle internal and environmental inflammatory stimuli
mediated mainly by the increased circulating levels of pro-
inflammatory cytokines. Inflammaging also generates
Reactive Oxygen Species (ROS) causing both oxidative
damage and eliciting an amplification of the cytokines'
release, thus perpetuating a vicious cycle resulting in a
chronic systemic pro-inflammatory state where tissue
injury and healing mechanisms proceed simultaneously
and damage slowly accumulates asymptomatically over
decades and is a major determinant both of the ageing
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process and of the development of age-associated diseases
[3,5-8].
Moreover, Claudio Franceschi, Tom Kirkwood, and Calo-
gero Caruso [1,8,9] as well as other authors, postulate that
both the ageing process and age-associated diseases are
late consequences of evolutionary programming for a pro-
inflammatory response mainly selected to resist infections
and for a successful response to wound healing in early
age, a view that has been discussed in the light of the
antagonistic pleiotropy theory [1,8,9]. Such a theory on
the evolution of aging postulates that senescence is the
late deleterious effect of genes that are beneficial in early
life. Evolutionary programming of the innate immune
system may act via selection on these genetic traits.
Inflammaging is triggered by the first line of biological
defense i.e. the innate immunity that operates by detec-
tion of a broad range of injuries inducing the activation of
inflammatory responses [1,4,7]. The mononuclear phago-
cytes lineage plays a pivotal role in innate immunity that
does not require clonal expansion of cell populations
[10]. Moreover, several other cell types contribute to
innate immunity by expressing pattern recognition recep-
tors, namely various scavenger and Tolllike receptors [11].
These cell encoded proteins recognize ligands from dam-
aged tissues and induce host responses by transmembrane
signals that activate NF-kB and mitogen dependent pro-
tein kinase pathway [12]. Toll-like receptor activation also
induces the expression of a wide variety of number of
genes encoding proteins, such as cytokines, with regula-
tory functions upon cell activations and tissue inflamma-
tion [13].
Here I propose that the already acquired knoledge in this
field may pave the way to a new chapter in the pathophys-
iology of autoimmunity: the auto [innate]immunity syn-
dromes, where Inflammaging may constitute the
subclinical paradigm of such a new chapter of autoimmu-
nity.
Moreover, while the innate immunity induced Inflam-
maging may remain sub-clinical as a determinant of the
ageing process, however, upon the presence of high
responder inflammatory genotypes (pro-inflammatory
cytokines versus anti-inflammatory cytokines), this auto
[innate]immunity syndrome may determine or at least
contribute to age-associated frailty and chronic diseases
including cardiovascular diseases, Alzheimer's disease,
insulin-resistance and diabetes, osteoarthritis, osteoporo-
sis, sarcopenia. Therefore, differently from the well known
chapter of conventional autoimmune diseases and syn-
dromes where the main actor is the adaptive immunity,
Inflammaging may constitute the subclinical paradigm of
a new chapter of autoimmunity, namely that arising from
an auto-immune inflammatory response of the innate-
immune-system an old actor of immunity and yet a new
actor of autoimmunity.
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